MDLN Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025
Revenue
7.9B
+2.2%
7.7B
+4.5%
7.4B
—
Cost of Revenue
5.9B
+8.4%
5.5B
-0.7%
5.5B
0
Gross Profit
1.9B
-13.1%
2.2B
+20.3%
1.8B
—
Operating Expenses
1.4B
-21.7%
1.8B
+28.3%
1.4B
—
R&D
0
0
0
—
SG&A
1.3B
-2.8%
1.3B
+5.5%
1.2B
—
Operating Income
500.0M
+26.6%
395.0M
-6.4%
422.0M
—
EBITDA
759.0M
+16.6%
651.0M
-3.7%
676.0M
0
Net Income
318.0M
+128.8%
139.0M
-41.8%
239.0M
—
EPS (Basic)
$0.23
+228.6%
$0.07
-56.3%
$0.16
—
EPS (Diluted)
$0.22
+214.3%
$0.07
-56.3%
$0.16
—
Shares (Diluted)
1.3B
+52.9%
860.9M
+4.4%
824.8M
-74.5%
3.2B
Medline (MDLN) — Financials